Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Next Science
Sydney, New South Wales, Australianextscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Next Science has developed and commercialized a proprietary non-toxic technology called XBIO that effectively eradicates both biofilm-based and free-floating bacteria. Their products have demonstrated efficacy in reducing surgical site and wound infections, with sustained effectiveness for up to five days in some applications. The company’s solutions are used to prevent infection by rinsing away debris/microorganisms or maintaining a moist environment conducive to healing.
- Therapeutic areas
- Infectious Diseases
- Modalities
- DeviceBiologicNon-pharmacological therapy
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on Next Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Next Science.